Pulse Biosciences (PLSE) Stock Price, News & Analysis

Company Overview

Pulse Biosciences, Inc. is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions. The CellFX System has received FDA 510(k) clearance and CE Mark approval in Europe, enabling commercial sales in the United States and select international markets. Beyond dermatology, Pulse Biosciences is exploring the NPS platform’s potential in oncology, immuno-oncology, wound healing and bacterial decontamination—areas that could benefit from nonthermal cellular disruption.

Founded in 2013 and headquartered in Hayward, California, Pulse Biosciences operates in North America and Europe, working closely with key opinion leaders in dermatology and medical research institutions. The company is led by President and Chief Executive Officer Vivek Chopra, who brings extensive experience in medical device development and commercialization. As Pulse Biosciences advances its clinical programs and expands its commercial footprint, it aims to establish TNP technology as a versatile tool across multiple therapeutic areas.

Key Stats

• Today's Range: $19.07 to $19.65
• 50-Day Range: $17.95 to $24.43
• 52-Week Range: $12.56 to $26.30
• Volume: 48,497 shs
• Average Volume: 310,526 shs
• Market Capitalization: $1.31 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Hold

Pulse Biosciences Stock Analysis - MarketRank™

Pulse Biosciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 600th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Pulse Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Pulse Biosciences has a consensus price target of $30.00, representing about 53.7% upside from its current price of $19.52.

Amount of Analyst Coverage

Pulse Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Pulse Biosciences are expected to decrease in the coming year, from ($1.51) to ($1.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulse Biosciences is -17.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulse Biosciences is -17.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulse Biosciences has a P/B Ratio of 16.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.84% of the float of Pulse Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Pulse Biosciences has a short interest ratio ("days to cover") of 11.32, which indicates bearish sentiment.

Change versus previous month

Short interest in Pulse Biosciences has recently decreased by 0.25%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulse Biosciences does not currently pay a dividend.

Dividend Growth

Pulse Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.50

News Sentiment

Pulse Biosciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Pulse Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for PLSE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Pulse Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pulse Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,994,400.00 in company stock.

Percentage Held by Insiders

74.60% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.95% of the stock of Pulse Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PLSE Stock Analysis - Frequently Asked Questions

How have PLSE shares performed this year?

Pulse Biosciences' stock was trading at $13.73 on January 1st, 2026. Since then, PLSE stock has increased by 42.1% and is now trading at $19.5150.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc (NASDAQ:PLSE) announced its earnings results on Monday, May, 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.40 million for the quarter, compared to analysts' expectations of $0.25 million.

When did Pulse Biosciences IPO?

Pulse Biosciences (PLSE) raised $20 million in an initial public offering on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

Who are Pulse Biosciences' major shareholders?

Top institutional shareholders of Pulse Biosciences include Griffin Asset Management Inc. (0.33%) and Inspire Investing LLC (0.04%). Insiders that own company stock include Robert W Duggan, Darrin Uecker, Mitchell E Levinson, Mitchell E Levinson, Burke Thomas Barrett and Kevin Patrick Danahy.
View institutional ownership trends.

How do I buy shares of Pulse Biosciences?

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulse Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/04/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PLSE
• CIK: 1625101
• Web: www.pulsebiosciences.com
• Phone: (510) 906-4600
• Fax: N/A
• Employees: 140
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Pulse Biosciences: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +54.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.78 million
• Net Margins: N/A
• Pretax Margin: -20,794.57%
• Return on Equity: -80.51%
• Return on Assets: -69.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.53
• Quick Ratio: 10.51

Sales & Book Value

• Annual Sales: $350 thousand
• Price / Sales: 3,788.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.19 per share
• Price / Book: 16.33

Miscellaneous

• Outstanding Shares: 68,220,000
• Free Float: 17,329,000
• Market Cap: $1.33 billion
• Optionable: Optionable
• Beta: 1.63